Gilead Sciences Inc (GILD)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need in the United States, Europe, and other international markets. Its marketed portfolio includes HIV-1 treatments such as Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo, along with therapies for chronic hepatitis C, primary biliary cholangitis, and chronic hepatitis B, including Epclusa, Livdelzi, and Vemlidy. The company also markets cell therapy and oncology products such as Tecartus, Trodelvy, and Yescarta, as well as AmBisome for serious invasive fungal infections and Veklury for COVID-19. Gilead has entered into collaboration, research, option, and license agreements with multiple biopharmaceutical and research partners, including Shenzhen Pregene Biopharma, Arcus Biosciences, Merck Sharp & Dohme, Janssen Sciences Ireland, Japan Tobacco, Everest Medicines, Merck & Co., Tentarix Biotherapeutics, Assembly Biosciences, Merus, Terray Therapeutics, and LEO Pharma. Incorporated in 1987, the company is headquartered in Foster City, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.